Key Points
- Casdin Partners Master Fund, L purchased 125,000 shares of Standard BioTools on Dec. 2 at $1.42 ($177,500) and now directly owns 71,875,000 shares valued at about $102.06 million, a 0.17% increase in its stake.
- The fund has been aggressively accumulating shares in recent weeks — buying over 10 million shares across multiple trades (including a 7,550,000-share block on Nov. 25 worth roughly $9.8 million).
- Market context: LAB traded up 3.8% to $1.50, has a market cap of $574.9M, and carries a consensus analyst rating of "Reduce" with an average target of $1.35.
Standard BioTools Inc. (NASDAQ:LAB - Get Free Report) Director Casdin Partners Master Fund, L acquired 75,000 shares of the company's stock in a transaction on Wednesday, December 3rd. The stock was purchased at an average cost of $1.44 per share, for a total transaction of $108,000.00. Following the completion of the purchase, the director directly owned 71,950,000 shares in the company, valued at $103,608,000. This trade represents a 0.10% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
Casdin Partners Master Fund, L also recently made the following trade(s):
- On Tuesday, December 2nd, Casdin Partners Master Fund, L bought 125,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.42 per share, for a total transaction of $177,500.00.
- On Thursday, December 4th, Casdin Partners Master Fund, L acquired 150,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.45 per share, with a total value of $217,500.00.
- On Tuesday, November 25th, Casdin Partners Master Fund, L acquired 7,550,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.30 per share, for a total transaction of $9,815,000.00.
- On Monday, November 24th, Casdin Partners Master Fund, L bought 150,000 shares of Standard BioTools stock. The shares were acquired at an average price of $1.43 per share, for a total transaction of $214,500.00.
- On Thursday, November 20th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.30 per share, with a total value of $585,000.00.
- On Wednesday, November 19th, Casdin Partners Master Fund, L purchased 350,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.28 per share, with a total value of $448,000.00.
- On Tuesday, November 18th, Casdin Partners Master Fund, L purchased 275,000 shares of Standard BioTools stock. The stock was acquired at an average price of $1.23 per share, for a total transaction of $338,250.00.
- On Monday, November 17th, Casdin Partners Master Fund, L acquired 225,000 shares of Standard BioTools stock. The shares were acquired at an average cost of $1.22 per share, for a total transaction of $274,500.00.
- On Friday, November 14th, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The stock was acquired at an average cost of $1.24 per share, with a total value of $310,000.00.
- On Thursday, November 13th, Casdin Partners Master Fund, L bought 450,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.20 per share, for a total transaction of $540,000.00.
Standard BioTools Trading Up 2.4%
Shares of NASDAQ:LAB traded up $0.04 on Friday, reaching $1.48. 263,968 shares of the company were exchanged, compared to its average volume of 1,692,908. The company has a 50-day moving average of $1.30 and a 200-day moving average of $1.26. The firm has a market cap of $567.23 million, a price-to-earnings ratio of -4.34 and a beta of 1.24. Standard BioTools Inc. has a 1-year low of $0.92 and a 1-year high of $2.25.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Intech Investment Management LLC boosted its position in shares of Standard BioTools by 6.1% in the second quarter. Intech Investment Management LLC now owns 149,018 shares of the company's stock worth $179,000 after acquiring an additional 8,519 shares during the last quarter. BNP Paribas Financial Markets increased its position in Standard BioTools by 50.3% during the second quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company's stock worth $36,000 after purchasing an additional 9,986 shares during the last quarter. HighTower Advisors LLC raised its stake in Standard BioTools by 10.8% during the first quarter. HighTower Advisors LLC now owns 102,791 shares of the company's stock worth $111,000 after purchasing an additional 10,000 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Standard BioTools by 103.6% in the 3rd quarter. Federated Hermes Inc. now owns 28,545 shares of the company's stock valued at $37,000 after purchasing an additional 14,523 shares during the last quarter. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Standard BioTools by 115.6% during the 1st quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 27,119 shares of the company's stock valued at $29,000 after buying an additional 14,541 shares during the period. 53.74% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of research firms have recently issued reports on LAB. Wall Street Zen downgraded shares of Standard BioTools from a "hold" rating to a "strong sell" rating in a research report on Saturday, November 8th. TD Cowen dropped their price target on Standard BioTools from $1.55 to $1.35 and set a "hold" rating for the company in a research report on Wednesday, November 5th. Cowen cut shares of Standard BioTools from a "buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Standard BioTools in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Reduce" and an average price target of $1.35.
Get Our Latest Report on LAB
About Standard BioTools
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
